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Previewsexpression exerted directly at the level of
p53 transcription? Because Bach2 and
Bcl6 recognize distinct DNA binding
sequences, what is the mechanism
underlying their competitive binding
behavior in shared target promoters? In
addition, at least under certain circum-
stances, Bach2 can shuttle between the
cytoplasm and nucleus in a redox sensi-
tive fashion (Chen et al., 2013; Muto
et al., 2002). Therefore, is Bach2 subcellu-
lar localization modulated during the pre-
BCR checkpoint? Since Bach2 has
emerged as a key regulator of the pre-
BCR checkpoint, these issuesmerit future
studies.284 Cancer Cell 24, September 9, 2013 ª201REFERENCES
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The effectiveness of cancer therapeutics targeting signal transduction pathways is comprised of a diversity
of mechanisms that drive de novo or acquired resistance. Two recent studies identify mTOR activation as a
point of convergence of mechanisms that cause resistance to inhibitors of the Raf-MEK-ERK and PI3K
signaling.A critical turning point in the fight against
advanced and metastatic melanomas
occurred just over a decade ago with the
discovery and characterization of the
BRAF activating mutation V600E in about
60% of melanomas (Davies et al., 2002).
This mutation causes constitutive activa-
tion of the B-Raf serine/threonine kinase,
resulting in aberrant and persistent acti-
vation of the Raf-MEK-ERK mitogen-
activated protein kinase cascade. Impor-
tantly, BRAF V600E correlated with poor
prognosis in patients with metastatic mel-
anoma. This prompted the development
and clinical evaluation of Raf and MEK
inhibitors for the treatment of BRAF
mutant metastatic melanoma (Salama
and Flaherty, 2013). The dramatic anti-
tumor activities of these inhibitors led toFood and Drug Administration approval
of two Raf (vemurafenib and dabrafenib)
and one MEK (trametinib) inhibitor for
the treatment of BRAF mutant melanoma
(Chapman et al., 2011; Flaherty et al.,
2012; Hauschild et al., 2012). Despite
the clinical success of these inhibitors,
resistance has limited their long-term clin-
ical impact. Although patient selection
based on BRAF mutation status defines
the patient population that would benefit
from Raf or MEK inhibition, 20%–50% of
patients showed no initial response, sug-
gesting de novo resistance in a significant
subset of melanoma patients (Chapman
et al., 2011; Hauschild et al., 2012).
Furthermore, even for patients who do
respond initially, within three months,
essentially all suffer from relapsed tumorsthat have acquired drug resistance. This
has led to numerous studies that have
identified multiple mechanisms of de
novo and/or acquired resistance to Raf,
inhibition with mechanisms that cause
ERK reactivation downstream of the
inhibitor block, as well as ERK-indepen-
dent mechanisms (Sullivan and Flaherty,
2013).
Corcoran et al. (2013) have recently
identified a mechanism that may provide
a more unifying model for the diverse
mechanisms already identified. Although
decreased phosphorylation of ERK
(pERK) has thus far been the standard
used to gauge tumor sensitivity in both
clinical and preclinical studies, Corcoran
et al. (2013) found that robust inhibition
of pERK was still observed in melanoma
Figure 1. mTOR-Driven Mechanisms of Cancer Cell Resistance to
Raf, MEK, and PI3K Inhibitors
A subset ofBRAFmutant melanomas possesses de novo resistances to Raf or
MEK inhibitor therapy, and essentially all cancers that are responsive initially
develop acquired resistance. A diversity of mechanisms of resistance has
been described (*) that most commonly cause ERK reactivation downstream
of the inhibitor block or activation of ERK-independent (X) mechanisms. Simi-
larly, only a subset of PIK3CA (encodes p110a) mutant cancers is responsive
to p110a isoform selective (BYL719) or pan-class I (GDC-0941) PI3K inhibitors.
In BRAF mutant (x) melanomas or PIK3CA (x) mutant breast carcinomas, acti-
vation of mTOR correlates with inhibitor resistance, and concurrent treatment
with an allosteric (RAD001/Everolimus) or catalytic (AZD8055) mTOR inhibitor
overcomes resistance. The phosphorylated state of S6, a substrate of
mTORC1-activated S6 kinase, provides amarker for resistance and response.
mTORC1 activation can be activated downstream of both PI3K and ERK as
well as by other mechanisms, possibly providing a point of convergence for
multiple mechanisms of resistance.
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Previewscell lines resistant to Raf or
MEK inhibitors, assayed by
measuring growth inhibition
and apoptosis induction.
Instead, Corcoran et al.
(2013) made the intriguing
discovery that levels of ribo-
somal protein S6 (pS6) phos-
phorylation, a key compo-
nent downstream of
mTORC1, can be used as a
marker of ERK-independent
resistance to Raf andMEK in-
hibitor treatment (Figure 1).
Analysis of melanoma cell
lines with different sensitiv-
ities to vemurafenib indicated
that while the common bio-
markers pERK and pAKT re-
sponded similarly, pS6
decreased in sensitive lines
but was sustained in insensi-
tive lines even upon
increasing doses of vemura-
fenib. To determine if MEK in-
hibition also required down-
regulation of pS6 for
sensitivity, cells were treated
with the MEK1/2 inhibitor
selumetinib in the presenceof activated mTOR, achieved by knock-
down of Tsc2, a major negative regulator
of mTORC1. This resulted in fewer
apoptotic cells, signifying that mTOR ac-
tivity protected cells against apoptosis
induced by MEK inhibition. Combination
of anmTOR catalytic inhibitor with vemur-
afenib increased cell death, further sug-
gesting that a combinatorial approach of
Raf and mTOR inhibition may prove effi-
cacious in vemurafenib-resistant mela-
nomas. Preclinical modeling using mouse
xenografts mirrored the cell line findings,
with pERK downregulation seen in both
sensitive and insensitive tumors, whereas
pS6 downregulation was only observed in
sensitive tumors.
The authors then addressed a critical
issue of whether these cell culture and
mouse model results could be translated
to cancer patients. Most intriguingly,
fine-needle aspiration (FNA) biopsies
from themouse xenograft tumors demon-
strated real-time decreases in pS6 upon
treatment. This approach was then
advanced to be successfully applied to
melanoma patients. In a time-sensitive
setting where treatment choices and
changes must be made quickly for thehealth of the patient, using FNAs to
assess biomarker status is ideal, because
it is minimally invasive and can be per-
formed multiple times. FNAs were then
used to probe pS6 and pERK response
to vemurafenib in metastatic melanoma
patients. This led to the promising result
of an almost 5-fold increase in progres-
sion-free survival seen in patients with
decreased pS6 in their tumors compared
to patients whose tumors did not.
Although these combined mTOR and
Raf inhibition studies have shown efficacy
in tumor cells and xenograft models, this
approach still must be assessed in human
patients. There is a trial currently recruit-
ing for advanced cancers that will assess
the combination of vemurafenib with the
mTOR inhibitor everolimus. Hopefully the
results from this clinical trial will support
the data reported by Corcoran et al.
(2013), showing improved patient
outcome once both Raf and mTORC1
are blocked.
Notably, another study in the same
issue of Science Translational Medicine
by Elkabets et al. (2013) reveals mTOR-
mediated resistance to p110a inhibition
in PIK3CA mutant breast cancers. Pre-Cancer Cell 24, September 9clinical and clinical evalua-
tion indicated that PIK3CA
mutation status provided an
incomplete genetic marker
for response to PI3K inhibition
(Bendell et al., 2012; Maira
et al., 2012). In these breast
cancer cells, inhibition of
mTOR by everolimus sensi-
tized tumor cells to
the p110a-specific inhibitor
BYL719. Similar to the results
reported by Corcoran et al.
(2013), mTORC1 activity and
pS6 were identified as impor-
tant biomarkers to p110a in-
hibitor response. Interest-
ingly, breast cancer cell lines
with acquired resistance to
BYL719 were established,
and these also displayed
enhanced mTORC1 activity
compared to their matching
control cells, indicating
kinome reprogramming to
p110a inhibitor treatment.
Depletion of mTOR via shRNA
from the acquired p110a in-
hibitor-resistant cells was suf-
ficient to prevent proliferation,and a combination of BYL719 and
mTORC1 inhibitor therapy prevented the
tumorigenic growth of BYL719 resistant
cells in mouse xenografts. Elkabets et al.
(2013) also examined breast cancer pa-
tient biopsies from an ongoing phase I
clinical trial of BYL719 treatment for
PIK3CA mutant solid tumors. Strikingly,
those patients that responded to
BYL719 treatment showed a loss of pS6
staining intensity in their tumors as
compared to biopsies before treatment
began, whereas those patients whose
tumors did not respond to BYL719 treat-
ment maintained high levels of pS6 during
treatment. Interestingly, biopsies from
two patients that initially responded to
BYL719 therapy, but later showed tumor
progression, displayed a return of pS6 to
levels similar to that seen prior to any
BYL719 treatment, further implicating
mTORC1 activation in the acquired resis-
tance to BYL719/p110a therapy.
In summary, the findings from these
two studies support mTOR activation as
a key driver of resistance to PI3K inhibi-
tion in PIK3CA mutant breast cancer
and resistance to Raf or MEK inhibition
in BRAF mutant melanoma. It will be, 2013 ª2013 Elsevier Inc. 285
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Previewsimportant to explore whether mTOR acti-
vation will act as a resistance mechanism
to inhibitors of other signaling compo-
nents in other cancer types. Additional
patient analyses and combination inhibi-
tor clinical trials will be needed to vali-
date the importance of mTORC1 activa-
tion as a biomarker to predict patient
response and mTOR inhibitor combina-
tion treatment to overcome resistance.
mTOR is regulated downstream of both
Raf and PI3K signaling and consequently
may define a key point of convergence of
the divergent resistance mechanisms
that have been identified. Finally, the sig-
naling mechanisms that cause mTOR
activation to drive resistance as well as
the downstream consequences of
mTOR signaling that promote resistance286 Cancer Cell 24, September 9, 2013 ª201are issues that remain to be fully
elucidated.
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